Cadrenal Therapeutics highlights Phase 2 data for CAD-1005 in heparin-induced thrombocytopenia, eyes CSA-AKI market
CVKD•CAD-1005 development plan and Phase 2 data
- Cadrenal Therapeutics sharpened its development plan for CAD-1005, targeting both heparin-induced thrombocytopenia and cardiac surgery-associated acute kidney injury.
- Phase 2 results were already presented at the ISTH 2026 Congress, supporting the drug’s clinical profile across clotting risk and kidney protection.
CSA-AKI market positioning and partnering potential
- The update follows a rival’s Phase 3 CSA-AKI program ending for lack of efficacy, improving CAD-1005’s first-in-class positioning in a $1 billion+ U.S. market.
- CAD-1005 is positioned as a Phase 3-ready, IV hospital critical-care therapy, supporting partnering talks such as out-licensing or co-development.
